[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapeutic-toxicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapeutic-toxicity":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,45,72,113,141,173,200,235,260,286,314,339,370,403,437,464,486,511,535,568,595],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100642857","effects-of-physical-training-on-cardiovascular-capacity-in-patients-undergoing-chemotherapy-for-cancer-100642857",false,"NCT07640087","Effects Of Physical Training On Cardiovascular Capacity In Patients Undergoing Chemotherapy For Cancer","Cancer","* Inclusion Criteria:\n\n  * Patients with a confirmed diagnosis of cancer who are undergoing chemotherapy treatment with anthracyclines;\n  * No physical exercise intervention for the past 3 months;\n  * Patients in the early or intermediate stages of cancer treatment;\n  * Adult patients (e.g., 18 to 59 years old) to avoid extreme variations in response to physical exercise;\n  * Clinically stable patients, without absolute contraindications to physical exercise (e.g., decompensated heart failure, severe arrhythmias);\n  * Patients able to participate in a supervised physical exercise program during the study period\n* Exclusion Criteria:\n\n  * Patients with severe pre-existing cardiac conditions (e.g., advanced cardiomyopathy, unstable angina) that prevent safe exercise practice;\n  * Patients with physical (e.g., inability to walk) or cognitive limitations that prevent participation in the physical exercise program;\n  * Patients undergoing treatments that may interfere with the results (e.g., recent thoracic radiotherapy, use of cardiotoxic agents unrelated to the study);\n  * Patients who already engage in regular and intense physical exercise, as this could interfere with the effects of the intervention.","ALL","18 Years","59 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Introduction: Cancer treatment, especially chemotherapy and radiotherapy, can lead to cardiovascular dysfunctions, such as a decrease in left ventricular ejection fraction and electrical dysfunction of the heart, which may consequently compromise patients' quality of life. In this context, physical exercise is a beneficial and promising tool, as it can prevent and minimize the deleterious effects of oncological therapies and their complications.\n\nObjective: To evaluate the effect of physical exercise on the prevention of cardiovascular diseases (CVD) induced by cancer treatment, analyzing the impact of supervised exercise on cardiovascular function and quality of life.\n\nMaterials and Methods: This is a clinical trial in which the sample will consist of 60 individuals undergoing cancer treatment, who will be stratified and randomized according to cancer stage classification into two groups: Intervention Group (IG) and Control Group (CG). The intervention will last 12 weeks, during which the IG will receive a prescription for physical exercises based on the FITT principle (frequency, intensity, time, and type), three times per week, while the CG will remain under usual care. Data will be presented using descriptive statistics, tests for two independent samples, and multivariate analysis, comparing the intervention effects between the two groups using R software version 4.3.3.\n\nExpected Results: Low incidence of CVD, improved heart rate variability, adherence to the exercise protocol, reduced risk for cardiovascular diseases, improvement in fatigue, functional capacity, and quality of life. Data will be collected at baseline, at the 6th week, and at the 12th week of intervention.",[27,28],"Cardiac Abnormalities","Chemotherapeutic Toxicity",[30,31,32],"QUALITY OF LIFE","PAIN","EXERCISE","NOT_YET_RECRUITING","2026-06-23",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":21},"2026-08-05",{"date":41,"type":21},"2027-12-01",{"name":43,"class":44},"Federal University of Maranhao","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100378429","daily-hand-held-vibration-therapy-100378429","NCT04207437","Daily Hand-Held Vibration Therapy","Daily Hand-Held Vibration Therapy for the Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN): A Pilot Study","Inclusion Criteria:\n\n1. 18 years or older at enrollment\n2. Able to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization\n3. Have completed chemotherapy ≥ 60 days prior to enrollment\n4. Were exposed to neurotoxic chemotherapy with one or more of the following agents in the following doses: Paclitaxel (cumulative dose: ≥ 300 mg\u002Fm2) Docetaxel (cumulative dose: ≥ 100 mg\u002Fm2) Nab-paclitaxel (cumulative dose: ≥ 750 mg\u002Fm2) Oxaliplatin (cumulative dose: ≥ 510 mg\u002Fm2) Carboplatin (cumulative dose: ≥ 600 mg\u002Fm2) Cisplatin (cumulative dose: ≥ 200 mg\u002Fm2) Vincristine (cumulative dose: ≥ 4 mg\u002Fm2) Bortezomib (cumulative dose: ≥ 16 mg\u002Fm)\n5. Continue to display evidence of sensory CIPN in the hands rated at a Grade ≥ 2 according the National Cancer Institute's Common Toxicity Criteria-Adverse Events (NCI-CTC-AE, Version 5.0) Scale ≥ 60 days post-chemotherapy\n6. If solid tumor cancer, must have non-metastatic cancer\n7. Agree to return to clinic for required study related measurements at specified intervals\n\nExclusion Criteria:\n\n1. Have pre-existing neuropathy affecting the hands not related to chemotherapy (e.g., carpal tunnel syndrome, nerve compression, etc.)\n2. Known diagnosis of diabetes mellitus.\n3. Known contraindications for vibration therapy to hands, including deep venous thrombosis of the upper extremity or ongoing skin infection.\n4. Will be receiving concurrent radiation of the upper-extremity",{"count":53,"type":21},16,[24],"The purpose of this pilot study is to determine the safety and feasibility of a daily 3-minute hand-held vibration therapy intervention to reduce the severity of CIPN in the hands. The investigators hypothesize that daily vibration therapy can reduce the severity of patient's CIPN in their hands and improve CIPN-related quality of life. The hope is that results from this study will provide early data on the feasibility, efficacy, and most importantly, safety, of daily 3-minute hand-held vibration therapy needed to justify future clinical trials examining vibration therapy as a potential option for treating CIPN in the future.",[57,14,58,28],"Neuropathy","Chemotherapeutic Drug - Induced Nephropathy",[57,60],"Vibration","RECRUITING","2026-05-26",{"date":64,"type":37},"2026-05-28",{"date":66,"type":37},"2021-12-06",{"date":68,"type":21},"2026-10",{"name":70,"class":44},"Indiana University",3,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":93,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":112},"100488116","effect-of-a-novel-topical-composition-on-the-incidence-of-severe-oral-mucositis-in-head--neck-cancer-radiated-patients-and-quality-of-life-assessed-by-proms-100488116","NCT05635929","Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.","Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs. A Two Phases Study, Part of STOP OM PROJECT. Phase 2, Single Arm, Interventional, Longitudinal, Clinical Trial.","STOPOMP","Inclusion Criteria:\n\nAcute Phase\n\n* Patients diagnosed with Head \\& Neck cancer who will undergo radiotherapy (with or without concomitant chemotherapy)\n* Patients who are able to read, understand, and complete the questionnaire.\n* Patients over 18 years of age.\n\nChronic Phase\n\n* Patients who have completed radiotherapy treatment at least 6 months before study enrollement.\n* Patients who are able to read, understand, and complete the questionnaire.\n* Patients over 18 years of age.\n\nExclusion Criteria:\n\nAcute Phase\n\n* Patients who are unable to properly use the products.\n* Patients who do not consent to participate in the study.\n* Patients who were being treated for another type of cancer.\n\nChronic Phase\n\n* Patients using medications such as pilocarpine, cevimeline, etc., to treat xerostomia.\n* Patients who do not consent to participate in the study.",{"count":81,"type":21},63,[24],"The use of a novel topical mucosa composition (XCM-OM118) comprising 2-(trimethylazaniumyl) acetate; (2R,3R,4S)-pentane-1,2,3,4,5-pentol; Hexadecanoic acid; (9Z, 12Z)-octadeca-9,12-dienoic acid; octadecanoic acid; (Z)-hexadec-9-enoic acid; (Z)-octadec-9-enoic acid) delivered as a gel and a mouthwash is to be studied in regard to its effect on the incidence of severe oral mucositis in Head \\& Neck cancer radiated patients. Patient reported outcome measures seem to be an effective tool to obtain a greater knowledge of the physical and emotional state of patients, being used in this study to assess quality of life of Head \\& Neck cancer radiated patients.",[85,86,87,88,89,90,91,28,92],"Oral Mucositis","Quality of Life","Mucositis","Pain","Speech","Saliva","Radiation Toxicity","Head and Neck Cancer",[85,94,95,88,96,97,98,99,100,92,101],"Cancer Therapy Toxic Effect","Cancer Support","Ulcers","Treatment Interruptions","Oral Mucosa","Radiotherapy","Chemotherapy","Severe Oral Mucositis","2026-04-10",{"date":104,"type":37},"2026-04-15",{"date":106,"type":37},"2022-10-11",{"date":108,"type":21},"2027-03",{"name":110,"class":111},"Mucosa Innovations, S.L.","INDUSTRY",1,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100624340","early-diagnosis-and-cardiovascular-risk-stratification-in-children-exposed-to-cancer-therapies-100624340","NCT07408362","Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Cancer Therapies","How to Improve Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Chemotherapy and\u002For Thoracic Radiotherapy? Multimodal Cardiological Evaluation and Biomarkers.","CTRCT-pedia","Inclusion Criteria:\n\n* History of chemotherapy and\u002For radiotherapy for an oncological condition or bone marrow transplantation (hematologic disease) after 01\u002F01\u002F2016.\n* Age \\\u003C 18 years at the time of treatment.\n* Cancer remission for more than one year.\n* Voluntary participation following comprehensive informed consent.\n* Signed informed consent from the patient (≥ 18 years) or from parents\u002Flegal guardians, with signed assent for minors aged 8 to 17.\n\nExclusion Criteria:\n\n* Active disease recurrence or relapse.\n* Current administration of antineoplastic therapy.\n* Withdrawal of consent or refusal to participate by the patient or their legal representatives.","2 Years","25 Years",{"count":124,"type":21},100,[24],"The goal of this prospective interventional study is to improve the detection of subclinical chronic Cancer Therapy-Related Cardiovascular Toxicity (CTRCT) and evaluate the added value of advanced cardioechography, ergospirometry, and specific biomarkers in pediatric cancer survivors (aged 2 to 25) who received potentially cardiotoxic treatments (chemotherapy\u002Fthoracic radiotherapy). The main questions it aims to answer are:\n\n* Can advanced echocardiography (including strain and myocardial work), ECG, and ergospirometry effectively diagnose earlier subclinical cardiac impairment in this population?\n* What is the prevalence of cardiovascular risk factors (including physical activity levels and biological markers like proBNP\u002Ftroponins)\n* Can new genetic or biological markers be identified to help optimizing the detection of CTRCT?\n\nAt time of follow-up, if they agree, participants will:\n\n* Complete validated questionnaires regarding quality of life, physical activity, and sedentary behavior.\n* Undergo a cardiopulmonary exercise test (ergospirometry) for those aged over 8 years.\n* Wear an accelerometer (ActiGraph GT3X) for 7 consecutive days to monitor physical activity.\n* Provide an additional blood sample during routine follow-up for the creation of a biobank dedicated to analyzing markers of senescence, fibrosis, apoptosis, and genetic polymorphisms.",[128,129,28,130,131],"Cancer Therapy-related Cardiovascular Toxicity","Childhood Cancer","Radiotherapy Side Effect","Cardiovascular Complication","2026-02-10",{"date":134,"type":37},"2026-02-13",{"date":136,"type":21},"2026-02-15",{"date":138,"type":21},"2033-12-31",{"name":140,"class":44},"Centre Hospitalier Universitaire de Liege",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":149,"sex":16,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":112},"100612399","evaluation-of-cardiac-and-endothelial-function-in-children-and-adolescents-treated-with-anthracycline-100612399","NCT07253077","Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline","Evaluation of Cardiac and Endothelial Function Measured by Laboratory Biomarkers and Echocardiographic and Endothelial Testing in Children and Adolescents Treated With Anthracyclines","CARDIO-PED","Inclusion Criteria for the patient group:\n\n* diagnosis of cancer during childhood (diagnosis made between 0 and 16 years of age);\n* age at enrollment greater than or equal to 6 years;\n* having received anthracycline chemotherapy;\n* disease remission for at least 1 year;\n* absence of known cardiac disease prior to anthracycline therapy;\n* absence of congenital heart disease.\n\nExclusion Criteria for the patient group:\n\n* disease remission for less than 1 year;\n* age less than 6 years at the time of enrollment;\n* presence of known comorbidities (cardiopulmonary diseases, neurological diseases, etc.).\n\nInclusion Criteria for the control group:\n\n* age at the time of enrollment: 6 years or older;\n* good health.\n\nExclusion Criteria for the control group:\n\n* having had oncological diseases;\n* having undergone thoracic radiotherapy;\n* having undergone anthracycline chemotherapy;\n* being under 6 years of age at the time of enrollment;\n* having known comorbidities (cardiopulmonary diseases, neurological diseases, etc.).",true,"6 Years","35 Years",{"count":153,"type":21},40,"OBSERVATIONAL","In recent decades, the survival rate of children with cancer has increased significantly thanks to personalized treatments and the adoption of international therapeutic protocols. However, along with this increase in survival, side effects related to these treatments on various organs and systems have been observed.\n\nAmong the most widely used chemotherapeutic agents in pediatric age, anthracyclines play a crucial role in the treatment of various forms of neoplasms (both haematological such as acute lymphoblastic leukemia or lymphomas, and solid tumors such as sarcomas). However, in addition to their excellent antineoplastic effect, they are burdened by the potential for cardiotoxicity. This cardiotoxicity manifests clinically with left ventricular systolic dysfunction and arrhythmias.\n\nAt the moment, international guidelines recommend long-term cardiac follow-up evaluations for this group of patients, even after treatment has concluded.The methods used in the cardiac follow-up of patients undergoing anthracycline therapy include echocardiography, cardiac magnetic resonance imaging, tests to assess endothelial function, and measurements of the biomarkers troponin and atrial natriuretic peptide. These methods can assess anthracycline-induced cardiac and endothelial damage once it has already occurred, but they cannot predict its onset nor can they study its pathogenesis.\n\nFurthermore, to date, no information is available regarding the possibility of using \"endothelial-mesenchymal transition\" biomarkers as predictors of the onset of anthracycline-induced cardiac damage.\n\nThis study analyzes these biomarkers as predictive tools for cardiac damage. Specifically, plasma levels of Serpin 3, THBS1, TGFbeta1, HIF1a, extracellular ICAM1, troponin, proBNP, fibrinogen, von Willebrand factor, and endothelin will be measured in patients treated with anthracycline. The concentrations of these biomarkers will be compared with the results of the echocardiogram and with the treatments performed in order to identify any relationships. Furthermore, plasma levels of Serpin 3, THBS1, TGFbeta1, HIF1a, extracellular ICAM1, troponin, proBNP, fibrinogen, von Willebrand factor, and endothelin will also be measured in a population of healthy subjects in order to obtain data on a possible relationship between the biomarkers and the anthracycline therapies performed.",[157,28,158],"Anthracycline Related Cardiotoxicity in Childhood Cancers","Childhood Cancer Survivors",[160,161,162,163],"Childhood cancer survivors","Anthracycline related cardiotoxicity","Chemotherapy long term side effects","Cancer survivor follow up","2025-11-19",{"date":166,"type":37},"2025-11-28",{"date":168,"type":21},"2025-11",{"date":170,"type":21},"2027-01",{"name":172,"class":44},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":112},"100604697","phase-4-the-effects-of-clostridium-butyricum-on-adverse-events-during-adjuvant-chemotherapy-for-colorectal-cancer-100604697","NCT07152886","The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer","The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Aged 18-70 years;\n* No restriction on gender;\n* Have completed radical resection for colorectal cancer (including open, laparoscopic, or robotic surgery), and assessed by the MDT as requiring adjuvant therapy primarily based on 5-FU and its derivatives or platinum-based regimens (including chemotherapy, targeted therapy, or radiotherapy);\n* ECOG performance status score of 0-2;\n* Signed informed consent\n\nExclusion Criteria:\n\n* Use of probiotics, prebiotics, synbiotics, or antibiotics within 2 weeks prior to enrollment;\n* Presence of psychiatric disorders or other conditions that prevent cooperation with the intervention;\n* Dysfunction of vital organs such as the liver, kidneys, or heart that renders the individual unsuitable for clinical research upon assessment, or inadequate bone marrow, liver, or renal function to undergo adjuvant therapy;\n* Participation in other clinical studies within 3 months prior to enrollment;\n* History of inflammatory bowel disease;\n* History of autoimmune diseases;\n* Pregnancy or breastfeeding;\n* Receipt of neoadjuvant therapy (including chemotherapy, radiotherapy, or targeted therapy) prior to surgery;\n* Underwent ostomy surgery during the operation (including temporary or permanent ostomy).","70 Years",{"count":182,"type":21},238,[184],"PHASE4","This study is a multicenter randomized controlled trial designed to investigate the effects of Clostridium butyricum on adverse events during adjuvant treatment for colorectal cancer.",[187,28],"Colorectal Cancer",[187,189,190],"adjuvant chemotherapy","Clostridium butyricum","2025-08-26",{"date":193,"type":37},"2025-09-03",{"date":195,"type":21},"2025-10-31",{"date":197,"type":21},"2027-12-31",{"name":199,"class":44},"The Affiliated Hospital of Qingdao University",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":208,"targetDuration":210,"studyType":154,"phases":4,"briefSummary":211,"conditions":212,"keywords":217,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":112},"100471350","patients-referred-to-the-chronic-pain-unit-for-palliative-treatment-with-ozone-therapy-between-2022-and-2025-100471350","NCT05417737","Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025","Prospective and Observational Study of Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025. (EPOOzo)","EPOOzo","Inclusion Criteria:\n\n1. Adults \\> = 18 years old.\n2. Patients submitted to the Chronic Pain Unit of the Hospital Universitario de Gran Canaria Dr. Negrín for symptomatic\u002Fpalliative treatment with ozone therapy because conventional treatment does not exist, it has been unsuccessful, or it is associated with high risk or high morbidity.\n3. After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment.\n4. Patients have no contraindications for ozone treatment.\n5. Patients have signed and dated the informed consent for the compassionated ozone treatment and the specific informed consent for this study\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years old.\n2. Psychiatric illness or social situations that would limit compliance with study requirements.\n3. Those who are incapable to fill in the scales used to measure variables.\n4. Hemodynamically or clinically unstable patients or uncontrolled severe illness.\n5. Uncontrolled cancer disease requiring chemotherapy treatment.\n6. Life expectancy \\\u003C 6 months\n7. Contraindication or disability or to attend scheduled treatments.\n8. Known allergy to ozone.\n9. Pregnancy at the time of enrollment (for systemic ozone therapy). 10 Hemochromatosis (for systemic ozone therapy).\n\n11\\. Known significant glucose-6-phosphate dehydrogenase deficiency (favism, acute hemolytic anemia) (for systemic ozone therapy).\n\n12\\. Patients who do not meet all the inclusion criteria",{"count":209,"type":21},105,"28 Weeks","The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms, who have been referred to the HUGCDN Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between June-2022 and December-2025",[91,28,213,214,215,216],"Chemotherapy-induced Peripheral Neuropathy","Delayed Wound Healing","Chronic Pain","Refractory Pain",[213,218,219,220,221,222,223,224,225],"Radiation-induced toxicity","Cancer-treatment side effects","Delayed wound healing","Chronic pain","Health-related quality of life","Anxiety and Depression","Ozone therapy","Refractory pain","2025-08-25",{"date":228,"type":37},"2025-09-02",{"date":230,"type":37},"2022-06-15",{"date":232,"type":21},"2026-06-30",{"name":234,"class":44},"Bernardino Clavo, MD, PhD",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":242,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":112},"100366605","clonal-hematopoiesis-is-a-risk-factor-for-chemotherapy-related-complications-100366605","NCT04053439","Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications","A Single Centre Cohort Study to Determine if Clonal Hematopoieses of Indeterminate Potential (CHIP) is a Risk Factor for Chemotherapy-Related Complications in Lymphoma Patients >= 60 Receiving Cytotoxic Chemotherapy","Inclusion Criteria:\n\n* Diagnosis of a lymphoma (ex: diffuse large B cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma\u002Fchronic lymphocytic leukemia, Hodgkin's lymphoma, peripheral T cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic lymphoma, hairy cell leukemia, Waldenstrom's macroglobulinemia, anaplastic large cell lymphoma, small lymphocytic lymphoma\u002Fchronic lymphocytic leukemia, and mantle cell lymphoma).\n* Commencing first or second-line cytotoxic chemotherapy for lymphoma with or without rituximab \\[ex: cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), cyclophosphamide, vincristine and prednisone (CVP), Fludarabine, fludarabine cyclophosphamide (FC), Bendamustine, cisplatin, cytarabine, dexamethasone (DHAP), etoposide, cytarabine, cisplatin, prednisone (ESHAP), gemcitabine, cisplatin and dexamethasone (GDP), Cladribine, Cyclophosphamide, Epirubicin, Vincristine, Prednisone (CEOP), dose-adjusted Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH)\\]\n\nExclusion Criteria:\n\n* Pre-existing diagnosis of myeloid neoplasm\n* Circulating lymphocyte count \\> 10 x 109\u002FL\n* Significant uncontrolled renal or hepatic impairment \\[\\>1.5 x upper limit of normal (ULN) bilirubin, \\>1.5 x ULN Alanine aminotransferase (ALT), \\>1.5 x ULN creatinine\\]\n* HIV\n* Active infection","60 Years",{"count":244,"type":21},188,"'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance, which are mutations in bone marrow stem cells that give that population of cells a survival or 'clonal' advantage for growth. This study investigates whether CHIP in lymphoma patients aged 60 years and older is a risk factor for chemotherapy-related complications like low blood counts, infections, cardiac events, hospitalizations, dose delays and dose reductions, and failure to recover normal blood counts after chemotherapy finishes.",[247,28],"Lymphoma",[249,100,247,250],"Clonal Hematopoiesis of Indeterminate Significance","Chemotherapy complications","2025-07-02",{"date":253,"type":37},"2025-07-08",{"date":255,"type":37},"2019-08-08",{"date":257,"type":21},"2026-09",{"name":259,"class":44},"Sunnybrook Health Sciences Centre",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":268,"maxAge":269,"enrollmentInfo":270,"targetDuration":121,"studyType":154,"phases":4,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":112},"100512997","adult-acute-lymphoblastic-leukemia-treated-with-pediatric-regimen-in-brazil-100512997","NCT05959720","Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil","Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study","BRALLA","Inclusion Criteria: Patients between 16 and 50 years-old with newly diagnosed ALL, negative for Philadelphia chromosome not previously treated (except for hydroxyurea, corticosteroids, or intrathecal chemotherapy) with 20% or more lymphoblasts in bone marrow or peripheral blood.\n\nExclusion Criteria:\n\n* Burkitt leukemia\n* Prior myeloproliferative disease\n* Philadelphia chromosome positivity through whichever methodology (RT-PCR, FISH, or conventional karyotype)\n* ECOG\\>2 (appendix 3)\n* Total bilirubin\\>2x upper limit of normal (ULN)\n* Transaminases\\>5x ULN\n* Creatinine\\>2,5 mg\u002Fdl\n* Positive serology for HIV or HTLV\n* Heart failure NYHA Class III or IV (appendix 4)\n* Severe psychiatric disorder which prevents adequate compliance\n* Prior treatment with intravenous chemotherapy\n* Refusal to participate in the study\n* Down syndrome","16 Years","50 Years",{"count":271,"type":21},180,"In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic\u002Ffollow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. The main goal of this study is to examine whether the implementation of a pediatric protocol under a prospective registry can increase event-free survival (EFS) and overall survival (OS) of newly diagnosed patients in the participating centers.",[274,275,276,28],"Acute Lymphoid Leukemia","Minimal Residual Disease","Gene Abnormality","2025-05-03",{"date":279,"type":37},"2025-05-07",{"date":281,"type":37},"2023-09-05",{"date":283,"type":21},"2030-06",{"name":285,"class":44},"Instituto do Cancer do Estado de São Paulo",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":16,"minAge":292,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":112},"100579610","at-home-cardiac-rehabilitation-for-adolescents-at-risk-for-heart-failure-100579610","NCT06826534","At-Home Cardiac Rehabilitation for Adolescents at Risk for Heart Failure","INCLUSION CRITERIA\n\n* Patients aged of 10-21 years at enrollment\n* Parent\u002Flegal guardian available for consent (if applicable), and patient available for assent and consent\n* History of anthracycline exposure +\u002F- radiation\n* Currently in remission, with at least 6 months off chemotherapy\n* Able to perform CPET\n* Baseline CPET with VO2 \\\u003C80% (at start of study, or CPET at CHLA after January 2020)\n* Smartphone compatible with Fitbit (own or parent\u002Flegal guardian's)\n* Ability to complete and send diary and Fitbit information on a weekly basis\n* Ability to participate in monthly virtual check-in visits\n* Baseline activity prior to intervention \\\u003C30min\u002Fday, 2x\u002Fweek\n\nEXCLUSION CRITERIA\n\n* Inability to obtain consent\u002Fassent\n* Unable to accurately perform quality of life survey independently\n* No other primary medical diagnosis (e.g., Down Syndrome, Wolff-Parkinson-White Syndrome, congenital heart disease) or history of cardiothoracic surgery\n* Contraindication to moderate activity (\\>3 METs). Examples include history of malignant arrhythmias, exercise-induced syncope, severe symptoms of HF (NYHA IV, ACC\u002FAHA Stage D)\n* Unable to perform CPET, echocardiogram, EKG, or obtain laboratory studies\n* Unable to perform mild activity for at least 0.5h\u002Fday and at least 2x\u002Fweek\n* Unable to come to hospital for study visits at 0 and 6 months\n* Unable to complete study-related surveys\n* Unable to complete and send diary and Fitbit information on a weekly basis\n* Unable to check-in monthly on virtual platform\n* On beta blockade\n* Pregnancy","0 Years","21 Years",{"count":295,"type":21},20,[24],"The goal of this clinical trial is to explore the impact that an at-home cardio-oncology rehabilitation (CORE) may have on short-term cardiovascular fitness and psychosocial wellness in pediatric cancer survivors. The main question it aims to answer are\n\n* To evaluate the efficacy of an at-home CORE model on short-term cardiovascular fitness and psychosocial wellbeing in adolescent cancer survivors.\n* To evaluate the exercise adherence rate among adolescents at risk for heart failure and assess barriers to compliance.\n* To explore which specific CORE resources are of most value to patients in creating sustainable healthy lifestyle modifications.\n* Hypothesis: Pediatric cancer survivors who implement exercise and dietary recommendations will demonstrate improvement in cardiovascular fitness and general wellness. A multidisciplinary team approach can facilitate adherence to a moderately rigorous exercise prescription, and thus enhance the health benefits of a CORE program at CHLA.\n\nParticipants will undergo cardiovascular studies and a quality-of-life survey prior to exercise intervention, and at the end of the 6-month study period.",[131,28],[300,301,302,303,304],"anthracycline exposure","cancer survivors","physical activity","pediatric oncology","cardiac rehabilitation","2025-02-12",{"date":307,"type":37},"2025-02-14",{"date":309,"type":37},"2023-10-20",{"date":311,"type":21},"2025-12-31",{"name":313,"class":44},"Children's Hospital Los Angeles",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":321,"minAge":17,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":112},"100573356","phase-2-herombopag-for-the-prevention-of-radio-chemotherapy-induced-thrombocytopenia-in-cervical-cancer-100573356","NCT06745219","Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer","Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer: A Single-arm Phase II Clinical Trial","Inclusion Criteria:\n\n1. Volunteer to participate in the trial and sign the informed consent\n2. Pathologically or cytologically confirmed cervical cancer\n3. aged 18 years or older\n4. ECOG performance score 0-1\n5. Stage IB3-IVA according to 2018 FIGO stage\n6. Patients receiving cisplatin-contained two-drug every-three week chemotherapy; minimum PLT value of the last chemotherapy \\\u003C50×109\u002FL, or ≥50 ×109\u002FL, but \\\u003C75×109\u002FL, meeting at least one high risk factor for bleeding: previous bleeding history; receiving cisplatin, gemcitabine, cytarabiine, anthracycline chemotherapy; combination of targeting or chemotherapy drugs likely to cause thrombocytopenia; tumor bone marrow infiltration; receiving radiotherapy, such as long bone or flat bone (pelvic or sternum)\n7. Survival expected to be ≥12 weeks, and can be treated with the concurrent chemotherapy regimen for at least one cycle\n8. Participants of reproductive age who agree to use reliable contraceptive methods throughout the study period (including male or female condoms, contraceptive foam, contraceptive gel, contraceptive film, contraceptive paste, contraceptive suppository, abstinence from sex, and insertion of an IUD); Female subjects who have undergone hysterectomy, bilateral salpingectomy, bilateral tubal ligation or more than 1 year postmenopausal and male subjects who have undergone bilateral vasectomy or ligation are excluded\n9. Participants can be treated with thrombopoietic drugs determined by researchers\n\nExclusion Criteria:\n\n1. Participants with other diseases of hematopoietic system, including but not limited to leukemia, primary immune thrombocytopenia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome\n2. Participants with thrombocytopenia occurred within the last 6 months due to causes other than CTIT, including but not limited to chronic liver disease, hypersplenism, infection\n3. Bone marrow invasion or metastasis\n4. History of severe cardiovascular disease within the last 6 months, such as congestive heart failure (NYHA heart function score III-IV), arrhythmias known to increase the risk of thromboembolism such as atrial fibrillation, after coronary stenting, angioplasty, and para-coronary transplantation, etc\n5. History of any arterial or venous thrombosis within the last 6 months\n6. Severe bleeding within 2 weeks, such as gastrointestinal or central nervous system bleeding, vaginal bleeding, etc\n7. Neutrophil absolute value \\\u003C1.5×109\u002FL, hemoglobin \\\u003C80g\u002FL, PLT\\\u003C90× 109\u002FL\n8. Significantly abnormal liver function :TBIL\\>1.5ULN(upper limit of normal), \\>3ULN for patients known to have Gilbert syndrome; ALT\\>2.5ULN or AST\\>2.5ULN\n9. Abnormal renal function: serum creatinine ≥1.5ULN or eGFR≤60 ml\u002Fmin(Cockcroft-Gault formula)\n10. Had received platelet infusion within 3 days\n11. known or expected allergy or intolerance to the active ingredient or excipient of hetropopar ethanolamine tablets\n12. HIV infected\n13. Pregnant or lactating women\n14. Participated in clinical trials of any other investigational drug or device within 28 days\n15. Inability to swallow, inflammatory bowel disease, or uncontrollable nausea, vomiting, diarrhea, or other gastrointestinal disorders that severely affect the administration and absorption of medications\n16. With a high risk for participants' safety or other conditions that may affect the efficacy evaluated by investigators","FEMALE",{"count":323,"type":21},30,[325],"PHASE2","Exploring and evaluating the efficacy of herombopag in preventing thrombocytopenia due to radiotherapy for cervical cancer",[328,329,130,28],"Thrombopenia","Cervical Cancer","2024-12-17",{"date":332,"type":37},"2024-12-20",{"date":334,"type":21},"2025-01-01",{"date":336,"type":21},"2025-07-30",{"name":338,"class":44},"Peking University Cancer Hospital & Institute",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":348,"conditions":349,"keywords":355,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":367,"locationsCount":369},"100545898","investigating-paclitaxel-toxicity-in-breast-cancer-the-roles-of-physical-activity-and-body-composition-100545898","NCT06387901","Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.","Dose-limiting Toxicities of Paclitaxel in Breast Cancer Patients: Studying Interactions Between Pharmacokinetics, Physical Activity, and Body Composition: an Observational Pilot Study.","PABTOX","Inclusion Criteria\n\n* Female patients with a diagnosis of breast cancer: Specifically targeting those diagnosed with stage II or III breast cancer, to understand the effects of paclitaxel within a somewhat uniform disease severity group.\n* Planned for 12 cycles of Paclitaxel (PTX) in a (neo-)adjuvant setting: The study focuses on patients scheduled to undergo a standard 12-week, once-a-week paclitaxel chemotherapy regimen as part of their treatment plan.\n* Age 18 or older in (pre-)menopausal status: Adult patients of any menopausal status are eligible, ensuring a wide demographic representation.\n* Prior taxane use is allowed if treatment in the adjuvant setting finished over a year ago: This criterion allows for the inclusion of patients who may have previously undergone taxane-based treatments, provided there has been a sufficient washout period to minimize the influence of prior treatments on the study outcomes.\n\nExclusion Criteria\n\n* Cognitive impairment (unable to understand test instructions): Ensuring participants can comprehend and follow study procedures and requirements is crucial for data integrity and participant safety.\n* Participation in clinical trials of experimental drugs: To avoid confounding effects from other investigational treatments and focus on the impact of standard-of-care paclitaxel therapy.\n* Documented intolerance or allergy to PTX (non-documented intolerance or allergy will lead to drop-out): Participants must be able to tolerate paclitaxel, as adverse reactions could compromise their safety and affect study results.\n\nInteracting drugs in home medication: Patients using medications known to interact with paclitaxel could experience altered drug metabolism or increased toxicity, potentially skewing study outcomes.\n\n* Male sex: The study is focused on breast cancer in female patients, as the disease's presentation, treatment, and outcomes can vary significantly between genders.\n* Age under 18 years: Ensuring all participants are legal adults helps adhere to ethical standards and regulatory requirements concerning consent and participation in clinical research.",{"count":153,"type":21},"This study looks into how a common breast cancer treatment, paclitaxel, can sometimes cause severe side effects that make it hard for patients to continue treatment. These side effects can significantly affect a patient's quality of life and even impact their recovery and overall health costs. What's interesting about this research is that it considers how a patient's lifestyle, specifically their physical activity levels and body makeup (like how much muscle and fat they have), might influence these side effects.\n\nThe researchers are doing a detailed study with 40 women receiving paclitaxel treatment, tracking how the drug is processed in their bodies and how their body composition and physical activity might play a role in the side effects they experience. They are using a special method to monitor drug levels in the blood and are also keeping tabs on the patients' health and physical activity through questionnaires and modern tracking devices.\n\nThe goal here is twofold: first, to better understand why these side effects happen to some people and not others, and second, to develop a model that can predict who might be at higher risk for these side effects based on their body composition, lifestyle, and how their body handles the drug. This could lead to more personalized treatment plans that could help reduce the risk of severe side effects and improve the overall treatment experience for patients with breast cancer.\n\nIn simpler terms, this research is trying to find a way to make breast cancer treatment with paclitaxel safer and more comfortable by considering how a person's lifestyle and body type might affect their reaction to the drug. This could make a big difference in helping patients complete their treatment successfully and with a better quality of life.",[350,351,28,352,353,354],"Breast Cancer","Paclitaxel Adverse Reaction","Chemotherapeutic Agent Toxicity","Body Weight","Physical Inactivity",[356,357,302,358,359,360],"breast cancer","chemotherapy","body composition","muscle mass","fat mass","2024-10-29",{"date":363,"type":37},"2024-11-01",{"date":365,"type":37},"2024-07-30",{"date":195,"type":21},{"name":368,"class":44},"Universitair Ziekenhuis Brussel",2,{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":383,"conditions":384,"keywords":387,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":112},"100519279","phase-3-concurrently-vs-sequentially-combined-haic-with-targeted-and-immunotherapy-in-potentially-resectable-hcc-100519279","NCT06041477","Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC","A Randomized Controlled Study of the Efficacy of Hepatic Arterial Perfusion Chemotherapy Concurrently Compared to Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable Intermediate and Advanced HCC","HAIC","Inclusion Criteria:\n\n1. Age ≥18 and ≤75 years;\n2. ECOG PS score of 0\\~1;\n3. Clinical or pathological diagnosis of hepatocellular carcinoma and meeting the stage IIa-IIIa of CNLC staging according to the relevant definitions in the 2015 edition of the Guidelines for Standardized Pathological Diagnosis of Primary Liver Cancer;\n4. Not having received previous treatment against hepatocellular carcinoma;\n5. Those who cannot be surgically resected after discussion by the multidisciplinary team of the participating centers , but have a potential chance of resection after conversion therapy, including: multiple tumors located in one lobe of the liver; portal vein cancer thrombus not reaching the main trunk, which can be resected together with the primary focus;\n6. Laboratory tests meet the following conditions, or the following conditions can be achieved with short-term treatment:\n\n   Neutrophil count ≥2.0×109\u002FL; Hemoglobin ≥ 100 g\u002FL; Platelet count ≥ 75 × 109\u002FL; Plasma albumin level ≥ 35 g\u002FL; Plasma total bilirubin less than 2 times the upper limit of normal; Plasma alanine aminotransferase (ALT) less than 3 times the upper limit of normal; Plasma aspartate aminotransferase (AST) less than 3 times the upper limit of normal; Plasma creatinine less than 1.5 times the upper limit of normal; Plasma prothrombin time is normal or exceeds the upper limit of normal value by ≤ 4 seconds; Prothrombinogen international normalized ratio (INR) ≤ 2.2;\n7. Patients were fully informed about the study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Those with severe comorbidity including cardiac, cerebral, pulmonary, renal, and other vital organ function damage, combined with severe infections or other serious concomitant diseases (\\> grade 2 CTCAE Version 5.0 adverse events), who cannot tolerate the treatment;\n2. Those with a history of other malignant tumors;\n3. Those with a history of related drug allergy;\n4. Those with known hypersensitivity to any component of the targeted and immunologic drugs to be applied;\n5. Those with a history of organ transplantation;\n6. Those who have received previous treatment targeting hepatocellular carcinoma (including interferon);\n7. Those with co-infection with HIV;\n8. Those with drugs abuse;\n9. Those who have had gastrointestinal bleeding or cardiovascular events within the last 30 days;\n10. Pregnant or breastfeeding women, or women of childbearing age who do not wish to use contraception;\n11. Persons with concomitant psychiatric disorders that preclude informed consent or affect acceptance of treatment;\n12. Other factors that may affect patient enrollment and assessment results.","75 Years",{"count":380,"type":21},540,[382],"PHASE3","The goal of this clinical trial is to compare HAIC concurrently with sequentially combined with targeted and immunotherapies in terms of efficacy and safety in patients with potentially resectable intermediate and advanced HCC (CNLC stage IIa\\~IIIa). The main questions it aims to answer are:\n\n* Does a \"strong combination\" regimen of three simultaneous treatments (HAIC, targeted agents and immunotherapy) definitely result in a higher surgical conversion rate and better survival benefit?\n* Can the combination of targeted and immunotherapies based on patients' response to HAIC therapy avoid over-treatment of some patients without affecting the surgical conversion rate and overall survival? Participants will be randomly assigned to receive either HAIC concurrently or sequentially combined with targeted and immunotherapies.\n\nResearchers will compare concurrent treatment group with sequential treatment group to see if there are different in terms of the conversion resection rate, long-term survival, and safety.",[385,386,28],"Hepatocellular Carcinoma","Chemotherapy Effect",[388,389,390,391,392,393],"Hepatic artery infusion chemotherapy","Tyrosine kinase inhibitors","Immune checkpoint inhibitors","Intermediate and advanced stage hepatocellular carcinoma","combined therapy","conversion resection","2024-08-25",{"date":396,"type":37},"2024-08-27",{"date":398,"type":37},"2023-10-31",{"date":400,"type":21},"2030-07",{"name":402,"class":44},"Sun Yat-sen University",{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":321,"minAge":17,"maxAge":180,"enrollmentInfo":410,"targetDuration":4,"studyType":22,"phases":412,"briefSummary":413,"conditions":414,"keywords":422,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":112},"100531268","safety-assessment-of-concurrent-radiotherapy-and-novel-systemic-therapy-for-breast-cancer-100531268","NCT06197581","Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer","RADIOCOM","Inclusion Criteria:\n\nECOG 0-2. Aged 18-70 years old. Pathologically diagnosed as breast cancer. Need to receive radiotherapy according to guidelines. Radiotherapy target volume included chest wall\u002Fbreast with or without lymph node regions.\n\nNeed to receive one of the following therapies according to guidelines, capetabine, CDK4\u002F6 inhibitor, PARP inhibitor , ICIs , HER2 inhibitors.\n\nExclusion Criteria:\n\nMale breast cancer. Allergy to the upper medicines before. Will receive trastuzumab alone during and\u002For after radiotherapy. With severe other disease.",{"count":411,"type":21},148,[24],"Radiation therapy is a crucial part in the comprehensive treatment of breast cancer. In recent years, emerging systemic treatment regimens such as HER 2 inhibitors, CDK 4\u002F6 inhibitors, PARP inhibitors, capecitabine and PD1 inhibitors have greatly improved the prognosis of breast cancer and has become the standard treatment for specific populations. A considerable number of patients require both radiotherapy and maintenance systemic therapy. However, it is not clear whether systemic therapy should be synchronized or suspended in radiotherapy，despite that previous basic research shows that some molecular drug therapy and radiotherapy has a clear synergy mechanism. There is an agent need for a definite evidence to evaluate the safety of synchronous treatment, to support clinical diagnosis and treatment and the next step of comprehensive treatment. The implementation of the new radiotherapy technology represented by IMRT takes into account the prescription dose homogenization and the minimization of normal tissue dosage, which provides a certain basis for the combination therapy. Based on the above conditions, this study intends to enroll patients between 18 and 70 years old with chest wall \u002F breast ± lymphatic drainage area and requiring capecitabine, CDK 4\u002F 6 inhibitor, HER2 targeted therapy or immunotherapy. Radiation and novel systemic therapies would be delivered concurrently. The study aimed at evaluating the safety of combined treatments.",[415,416,28,417,418,419,420,421],"Breast Cancer, Familial Male","Radiotherapy; Complications","Immune Checkpoint Inhibitor","CDK4\u002F6 Inhibitor","Trastuzumab","Pertuzumab","PARP Inhibitor",[350,99,423,424,419,420,425,426,427],"Adverse events","Capecitabine","Immune checkpoint inhibitor","CDK4\u002F6 inhibitor","PARP inhibitor","2024-08-19",{"date":430,"type":37},"2024-08-21",{"date":432,"type":37},"2024-01-12",{"date":434,"type":21},"2027-01-15",{"name":436,"class":44},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":438,"slug":439,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":22,"phases":446,"briefSummary":447,"conditions":448,"keywords":451,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":4},"100550634","phase-2-semaglutide-in-auto-hsct-100550634","NCT06449625","Semaglutide in Auto-HSCT","Semaglutide Treatment for PRevention Of Toxicity in High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation","PROTECT","Inclusion Criteria:\n\n* Referral for auto-HSCT for relapsed diffuse large B-cell lymphoma or follicular lymphoma\n* Age ≥ 18 years\n* BMI ≥ 18.5\n* ECOG performance status\\* ≤ 2\n* Literate in Danish and\u002For English\n\nExclusion Criteria:\n\n* Diabetes\n* Inflammatory bowel disease\n* Previous or current gastrointestinal malignancy\n* Personal or family history of medullary thyroid carcinoma or MEN syndrome\n* Genetic disorders with defective tissue repair (e.g., Fanconi anaemia)\n* History of pancreatitis (acute or chronic)\n* Renal impairment measured as eGFR value of \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n* Impaired liver function, defined as alanine aminotransferase ≥ 2.5 times upper normal limit at screening\n* Known or suspected hypersensitivity to semaglutide or other GLP-1RA\n* Pregnant or nursing females",{"count":153,"type":21},[325],"The primary objective of this clinical trial is to ievaluate the effect of semaglutide (GLP-1 receptor agonist) in reducing intensity of gastrointestinal (GI) mucositis in patients undergoing high-dosage chemotherapy followed by autologous (auto) haematopoietic stem cell transplantation (HSCT). The secondary objective is to evaluate the effect and safety of semaglutide in reducing gut barrier injury and systemic inflammation in patients undergoing auto-HSCT.\n\nStudy design:\n\nThe study is designed as a randomized, double-blind, placebo-controlled, phase 2, two-centre investigator-initiated clinical study.\n\nPatients referred for treatment with high-dose chemotherapy and auto-HSCT will be randomized in a 1:1 manner to receive either semaglutide or placebo. The study includes a run-in period 3 to 4-week low-dose period with semaglutide subcutaneously (s.c.) 0.25 mg once-weekly (QW) prior to high-dose chemotherapy treatment followed by a period of 4 to 5 weeks with semaglutide 0.5 mg QW. Total duration of treatment with investigational drug will be 8 weeks. Total study duration for the individual patients will be 20-22 weeks, including a 2-4-week screening period and 10 weeks of follow-up.\n\nStudy population:\n\nA planned total number of 40 patients will be randomized.",[449,450,28],"Intestinal Mucositis","Inflammation",[452,453,454],"Gut epithelial barrier","Chemotherapy-induced toxicity","Growth factor","2024-06-03",{"date":457,"type":37},"2024-06-10",{"date":459,"type":21},"2024-08-12",{"date":461,"type":21},"2027-02-01",{"name":463,"class":44},"Klaus Gottlob Müller",{"id":465,"slug":466,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":321,"minAge":17,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":112},"100510031","fasting-mimicking-diet-fmd-in-conjunction-with-chemotherapy-in-advanced-ovarian-cancer-100510031","NCT05921149","Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer","A Randomized Controlled Study of a Fasting Mimicking Diet (FMD) in Conjunction With Combination Carboplatin and Paclitaxel in the Treatment of Patients With Advanced or Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. All patients with advanced ovarian, fallopian tube and primary peritoneal carcinomas deemed appropriate candidates for neoadjuvant chemotherapy and patients with recurrent, platinum-sensitive disease (as defined by an interval of at least 6 months following completion of last platinum-based chemotherapy prior to disease relapse or progression)\n3. ECOG Performance Status of 0, 1 or 2.\n4. Adequate bone marrow reserve (absolute neutrophil count (ANC) ≥1.5 x 109\u002FL and platelet count ≥100 x 109\u002FL).\n5. Adequate renal function defined as creatinine ≤1.5 x laboratory upper limit of normal (ULN).\n6. Adequate hepatic function defined as:\n\n   Bilirubin ≤1.5 x ULN ALT and AST ≤3 x ULN\n7. BMI ≥19 kg\u002Fm2\n\nExclusion Criteria:\n\n1. Patients with malnutrition and\u002F or BMI \\\u003C19\n2. Patients with active eating disorders (as identified by history of pre-enrollment nutrition screen)\n3. Diabetes mellitus requiring medication management (both insulin and non-insulin requiring). Patients with diabetes mellitus controlled by diet alone (i.e. patients not requiring anti-glycemic medications) are NOT excluded and are eligible for participation.\n4. Allergy to component of fasting mimicking diet (FMD)\n5. Patients with recurrent ovarian, fallopian tube and primary peritoneal carcinomas with relapse within 6 months of completion of last platinum-based chemotherapy regimen (i.e. patients with platinum-resistant disease)",{"count":472,"type":21},170,[24],"Rates of grade 3-4 toxicity with carboplatin and paclitaxel chemotherapy range 26-84%. Interventions to reduce toxicity are needed.\n\nShort term fasting protects against toxic effects of chemotherapy without decreasing efficacy. In a prospective clinical trial of breast cancer patients randomized to FMD or regular diet during chemotherapy, less antiemetic was required in the FMD group; radiographic and pathologic responses were better in this group.\n\nThis trial tests whether platinum-taxane chemotherapy combined with a FMD in advanced and recurrent ovarian, fallopian tube and primary peritoneal cancer patients is associated with decreased toxicity and\u002F or improved tumor response to therapy.",[476,28],"Ovarian Cancer","2024-05-05",{"date":479,"type":37},"2024-05-07",{"date":481,"type":21},"2024-05-25",{"date":483,"type":21},"2031-06-01",{"name":485,"class":44},"Endeavor Health",{"id":487,"slug":488,"hasResults":11,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":149,"sex":16,"minAge":494,"maxAge":180,"enrollmentInfo":495,"targetDuration":4,"studyType":22,"phases":497,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":507,"leadSponsor":509,"locationsCount":369},"100536887","effects-of-exercise-training-in-survivors-of-lymphoma-100536887","NCT06270667","Effects of Exercise Training in Survivors of Lymphoma","The LYMfit Study: Exercise Training to Prevent Cardiovascular Disease in Lymphoma Survivors","LYMfit","Inclusion Criteria Lymphoma participants:\n\n* Listed in relevant registers\n* Confirmed lymphoma diagnosis (i.e., Hodgkin lymphoma and aggressive non-Hodgkin lymphoma)\n* Completed treatment in the past two to five years without relapse or second cancer\n* Previous anthracycline treatment with or without mediastinal radiation\n* No severe cancer-related fatigue (per self-report)\n\nInclusion Criteria Lymphoma participants and non-cancer reference group:\n\n* Currently not performing \\>75 minutes\u002Fweek of aerobic exercise\n* Willing and able to adhere to all study procedures.\n\nExclusion Criteria Lymphoma participants:\n\n* Relapse since diagnosis\n* A history, or current presence, of another diagnosis of invasive cancer of any kind\n\nExclusion Criteria Lymphoma participants and non-cancer reference group:\n\n* Presence of any uncontrolled- or recent cardiovascular disease\n* Has undergone heart surgery\n* Uses a pacemaker\n* Pregnancy\n* Unable to read and understand Swedish (applicable for the Swedish site only)\n* Unable to read and understand Norwegian (applicable for the Norwegian site)\n* Any physical or mental health condition restricting adherence to study protocol","20 Years",{"count":496,"type":21},280,[24],"This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and sex-matched individuals with no prior history of malignant diseases.",[247,500,501,502,28],"Physical Exercise","Cardiotoxicity","Cardiovascular Diseases","2024-03-20",{"date":505,"type":37},"2024-03-22",{"date":503,"type":37},{"date":508,"type":21},"2028-09-01",{"name":510,"class":44},"Norwegian School of Sport Sciences",{"id":512,"slug":513,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":16,"minAge":242,"maxAge":4,"enrollmentInfo":519,"targetDuration":521,"studyType":154,"phases":4,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":112},"100458120","danish-elder-lymphoma-patient-hematopoietic-investigation-100458120","NCT05245487","Danish Elder Lymphoma Patient Hematopoietic Investigation","Chemotherapy-induced Genomic Damage in Elderly Patients With Lymphoma: Prevalence, Evolution, and Clinical Consequences","DELPHI","Inclusion Criteria:\n\n* Diagnosis of r\u002Fr B-cell Non-Hodgkin lymphoma\n* In need of systemic treatment with second (2.) or higher line of active therapy for lymphoma\n* 60 years of age or older (no age maximum)\n\nExclusion Criteria:\n\n* Unable to give written consent\n* Non-Danish citizens",{"count":520,"type":21},300,"10 Years","Every year approximately 300 Danish patients die from lymphoma. The median age at diagnosis is 70 years. Lymphoma can be efficiently treated with chemotherapy, and potentially cured. However, sufficient treatment is often hampered by toxicity, especially in elderly patients. It is also well known that the main risk factor for dying of lymphoma is age. New biologically targeted therapies with fewer side effects are becoming available for lymphoma treatment, however it is currently difficult to delineate which patients benefit from chemotherapy and which should be treated with novel expensive therapies.\n\nRecently, it has been discovered that chemotherapy can provoke growth of patient blood cells with DNA mutations. This leads to increased rates of treatment side effects and excess mortality. These defects have so far only been examined in younger patients below 70 years of age, where they are found in roughly 10% of patients. It remains unknown to what extent elderly individuals are affected, but the investigators hypothesize that the proportion and negative effects are much larger.\n\nTherefore, the investigators propose to investigate the frequency and evolution of these DNA mutations during chemotherapy in a prospective study of patients, who are either above 60 years of age and previously treated with chemotherapy for lymphoma in a nation-wide collaboration.\n\nBy using blood samples, advanced genetic analyses and patient-reported questionnaires, the investigators will study\n\n* The prevalence of these mutations and their consequences for patient wellbeing, treatment side effects (such as anemia, infections etc.) and mortality\n* The kinetics of these mutations during and after treatment, and explore possible evolutionary patterns of the inferred damages The investigators expect to include 300 patients in the study and that the first results will be ready in a timeframe of 4 years. The investigators hope to obtain new insights in the risk factors for physiological and mental health in lymphoma patients and thereby pave the way for improvements in wellbeing and survival of this underserved population.",[247,524,525,28],"Chemotherapy-induced Neutropenia","Chemotherapy-Related Leukemia","2023-12-18",{"date":528,"type":37},"2023-12-22",{"date":530,"type":37},"2022-01-01",{"date":532,"type":21},"2035-01-01",{"name":534,"class":44},"Rigshospitalet, Denmark",{"id":536,"slug":537,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":22,"phases":545,"briefSummary":546,"conditions":547,"keywords":550,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":567},"100420432","aerobic-fitness-or-muscle-mass-training-to-improve-colorectal-cancer-outcome-100420432","NCT04754672","Aerobic Fitness or Muscle Mass Training to Improve Colorectal Cancer Outcome","Aerobic Fitness or Muscle Mass Training to Improve Colorectal Cancer Outcome (AMICO). The Effects of Exercise on Chemotherapy Dose Modification and Progression Free Survival in Patients With Metastatic Colorectal Cancer","AMICO","Inclusion Criteria:\n\n* mCRC with indication for palliative chemotherapy\n* scheduled for treatment with first-line doublet or triplet chemotherapy, according to the national guideline\n* able and willing to give written informed consent.\n\nExclusion Criteria:\n\n* life expectancy \\\u003C6 months\n* unable to perform basic activities of daily living such as walking or biking\n* presence of cognitive disorders or severe emotional instability (e.g., Schizophrenia, Alzheimer, alcohol addiction);\n* presence of other disabling co-morbidities that might hamper physical exercise (e.g. heart failure (NYHA classes 3 and 4), chronic obstructive pulmonary disease (COPD, gold 3 and 4), orthopaedic conditions and neurological disorders (e.g., hernia, paresis, amputation, active rheumatoid arthritis);\n* insufficient mastery of the Dutch language;\n* presence of serious cardiovascular or cardiopulmonary conditions (e.g. unstable angina, arrhythmia or valve disease) such that exercise safety is at risk, as judged by the treating physician.\n* Already participating in structured vigorous aerobic and\u002For resistance exercise ≥ 2 times per week comparable to our intervention",{"count":544,"type":21},228,[24],"Evidence from randomized controlled trials shows that exercise during cancer treatment benefits physical fitness, fatigue and quality of life. Since the effect of exercise on clinical outcome is currently unknown, exercise is not included as integral part of standard cancer care. Moreover, evidence regarding the optimal exercise prescription in terms of type and dose is lacking.\n\nTo maintain quality of life in patients receiving palliative treatment with chemotherapy, toxicity-induced modifications in the prescribed chemotherapy dose are common. Such modifications - occurring in 40% of patients with metastatic colorectal cancer - may reduce benefit of treatment. The investigators hypothesize that exercise prevents chemotherapy dose modifications by reducing toxicity and enhancing psychological strength. Additionally, based on studies in rodents and preliminary data in patients with cancer, the researchers hypothesize that exercise has beneficial effects on the functionality of the natural killer cells, which play an important role in the innate immune defense against cancer. Both, fewer dose modifications and improved immune function may improve progression-free survival.\n\nThis study is a three-armed trial comparing resistance exercise, aerobic interval exercise and usual care in patients with metastatic colorectal cancer to select the optimal exercise prescription for preventing chemotherapy dose modifications. The trial will use a Bayesian adaptive multi-arm multi-stage design with several interim analyses after which an ineffective study arm can be dropped early. This novel design makes the trial more efficient and reduces patients' exposure to suboptimal study arms.\n\nEvidence regarding the exercise effects on i) clinical outcome, ii) the optimal exercise prescription, and iii) the underlying mechanisms, elucidates the potential of exercise to boost benefit from chemotherapy treatment. This evidence provides leads to improve progression-free survival and quality of life of patients suffering from one of the leading causes of cancer death worldwide.",[187,28,548,549],"Survivorship","Lifestyle",[551,552,553,554,555,556,557],"Exercise","Muscle strength","Cardiorespiratory fitness","Colorectal cancer","Chemotherapy dose modification","Progression free survival","Bayesian adaptive trial","2023-11-16",{"date":560,"type":37},"2023-11-18",{"date":562,"type":37},"2021-03-02",{"date":564,"type":21},"2026-12",{"name":566,"class":44},"Radboud University Medical Center",13,{"id":569,"slug":570,"hasResults":11,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":11,"sex":321,"minAge":17,"maxAge":576,"enrollmentInfo":577,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":578,"conditions":579,"keywords":583,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":594},"100510041","understanding-cardiac-events-in-breast-cancer-100510041","NCT05921279","Understanding CARdiac Events in Breast Cancer","Understanding CARdiac Events in Breast Cancer - Pilot Cardio-Oncology Assessment and Surveillance Pathway for Breast Cancer Patients","UCARE","Inclusion Criteria:\n\n* Women aged ≥ 18 years\n* Ability to read and understand English\n* Breast Cancer Stage I- III planned to receive systemic chemotherapy\n\nExclusion Criteria:\n\n* Patients not for systemic chemotherapy with curative intent\n* Patients who are unable to co-operate with the study protocol\n* Patients who are unable to give informed consent","90 Years",{"count":124,"type":21},"In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime. There is evidence that female breast cancer survivors are more likely to die of cardiovascular disease than their age-matched counterparts.\n\nThis research is focused on evaluating pathways for identifying, managing, and overcoming side effects of cancer therapies that can negatively impact quality-of-life and overall outcomes for women during and after cancer treatment. The Cardio-oncology research team at GUH plan to capitalize on their expertise in both cancer care and cardiology to develop a care pathway for cancer patients who are at increased risk of developing heart disease.",[350,501,580,28,581,582],"Cardiomyopathies","Heart Failure","Oncology",[584],"Cardio oncology","2023-07-24",{"date":587,"type":37},"2023-07-25",{"date":589,"type":37},"2023-01-14",{"date":591,"type":21},"2026-07",{"name":593,"class":44},"National University of Ireland, Galway, Ireland",4,{"id":596,"slug":597,"hasResults":11,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":149,"sex":16,"minAge":603,"maxAge":604,"enrollmentInfo":605,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":606,"conditions":607,"keywords":615,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":112},"100503846","investigating-cognitive-impairment-in-young-patients-with-cancer-prospectively-100503846","NCT05840575","Investigating Cognitive Impairment in Young Patients With Cancer Prospectively","A Multidisciplinary Neuroscience Approach to Investigate Cognitive Impairment in Young Patients With Cancer Prospectively","MyBrain","Inclusion Criteria:\n\n* Patients who are newly diagnosed with a non-CNS cancer and will undergo chemotherapy at University Hospital Copenhagen, Rigshospitalet.\n* At the age of 7-29 years at diagnosis\n* Each patient is matched (1:1) with a control participant within 24 months of age. The controls are recruited from the patient's own social circle and can be a friend, partner, or close family (sibling or cousin).\n\nExclusion Criteria:\n\n* Unable to speak and understand Danish\n* Severe intellectual disability or mental health disorder that hinders participation\n* Brain metastases,\n* Terminal illness\n* Have had a previous chemotherapy or radiotherapy treatment","7 Years","29 Years",{"count":124,"type":21},"The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer. The tests include 1) cognitive skills such as memory and attention; 2) the brain's electrical activity; 3) and biological markers related to brain function.\n\nThe aim of the study is to better understand the trajectories of cognitive functioning and measures that have been associated with cognitive impairment in patients treated with chemotherapy.",[608,28,609,14,129,610,611,612,613,614],"Chemotherapy-Related Cognitive Impairment","Chemo-brain","Hodgkin Lymphoma","Non Hodgkin Lymphoma","Testicular Cancer","Sarcoma","Leukemia",[616,617,618,619],"Cognition","Neuropsychology","Electroencephalogram","Biomarkers","2023-04-24",{"date":622,"type":37},"2023-05-03",{"date":624,"type":37},"2022-03-01",{"date":626,"type":21},"2027-03-01",{"name":534,"class":44}]